PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound care, announced today that Edward J. Quilty, the Company’s chairman and chief executive officer, will present a corporate overview and update at the 26th Annual ROTH Conference on March 11, 2014 at 3:30 p.m. Pacific time. The conference is being held at the Ritz Carlton, Laguna Niguel in Dana Point, Calif. from March 9 through March 12.
To listen to the presentation investors may visit the investor relations section of Derma Sciences’ website at www.dermasciences.com. An archived audio of the discussion will also be available on Derma Sciences’ website for 90 days.
About Derma Sciences, Inc.
Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products; advanced wound care dressings to address chronic wounds including diabetic ulcers; and traditional dressings. The Company has begun its Phase 3 clinical trials in diabetic foot ulcer healing with DSC127, based on excellent Phase 2 data. During the third quarter of 2014 Derma Sciences expects to begin marketing AmnioMatrix®, a portfolio of two novel human placental-derived tissue products for wound healing. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ® is its gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for barrier protection against microbes and other contaminants.
For more information please visit www.dermasciences.com.